Conjugate Vaccine Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-02-16　·　151 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 25,966 Mn
2033 年預估規模: USD 49,220 Mn
年複合成長率 CAGR: 9.6%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-02-16頁數 151報告編號 CMI2697

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Conjugate Vaccine Market, By Product Type (Monovalent Conjugate Vaccine, Multivalent Conjugate Vaccine), By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid), By Pathogen Type (Bacterial, Viral), By Patients Type (Pediatric, Adults), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

報告摘要

Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen. Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body’s immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13. Market Dynamics Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit. Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India. Key features of the study • This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 – 2030), considering 2021, as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players • It profiles key players in the global conjugate vaccine market based on following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans • Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics • The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market Market Segmentation • Product Type Insights (Revenue, USD Mn, 2026 - 2033) o Monovalent Conjugate Vaccine o Multivalent Conjugate Vaccine • Disease Indication Insights (Revenue, USD Mn, 2026 - 2033) o Pneumococcal o Influenza o Meningococcal o Typhoid • Pathogen Type Insights (Revenue, USD Mn, 2026 - 2033) o Bacterial o Viral • Patients Type Insights (Revenue, USD Mn, 2026 - 2033) o Pediatric o Adults • Regional Insights (Revenue, USD Mn, 2026 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Sanofi S.A o Pfizer, Inc. o Merck & Co., Inc. o GlaxoSmithKline plc. o Bharat Biotech o Serum institute of India Pvt. Ltd. o Biological E. Limited o Bio-Med o Bavarian Nordic o CSL Limited o Novartis AG o Vaxcyte o GSBPL o Taj Pharmaceuticals Limited o Bavarian Nordic

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description o Market Definition and Scope o Executive Summary  Market Snapshot, By Product Type  Market Snapshot, By Disease Indication  Market Snapshot, By Pathogen Type  Market Snapshot, By Patient Types  Market Snapshot, By Region o Coherent Opportunity Map (COM) 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics  Drivers  Restraints  Market Opportunities o Impact Analysis o Market Trends o Key Developments o Product Pipeline Analysis o Investments and Government Initiatives o GAVI and PATH Program Details o Merger and Acquisition o Regulatory Scenario o PORTER’S Five Forces o PEST Analysis 4. Global Conjugate Vaccine Market, By Product Type, 2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Monovalent Conjugate Vaccine  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Multivalent Conjugate Vaccine  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 5. Global Conjugate Vaccine Market, By Disease Indication, 2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Pneumococcal  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Influenza  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Meningococcal  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Typhoid  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 6. Global Conjugate Vaccine Market, By Pathogen Type, 2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Bacterial  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Viral  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 7. Global Conjugate Vaccine Market, By Patient Type,2026-2033, (USD Mn) o Overview  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Paediatric  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends o Adult  Market Share Analysis, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, 2021 – 2033  Segment Trends 8. Global Conjugate Vaccine Market, By Region, 2026-2033, (USD Mn) o Introduction  Market Share Analysis, By Region, 2025, 2028, and 2033 (%)  Y-o-Y Growth Analysis, For Region, 2021 - 2033 o North America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)  Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o U.S. o Canada o Latin America  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)  Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o Brazil o Mexico o Argentina o Rest of Latin America o Europe  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)  Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o U.K. o Germany o Italy o France o Spain o Russia o Rest of Europe o Asia Pacific  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)  Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o China o India o Japan o ASEAN o Australia o South Korea o Rest of Asia Pacific o Middle East  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)  Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o GCC o Israel o Rest of Middle East o Africa  Market Share Analysis, By Country, 2025, 2028 and 2033 (%)  Y-o-Y Growth Analysis, For Country, 2021 - 2033  Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)  Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)  Market Size and Forecast, By Country, 2026-2033, (USD Mn) o North Africa o Central Africa o South Africa 9. Competitive Landscape o Heat Map Analysis o Company Profile  Sanofi S.A o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Pfizer, Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Merck & Co., Inc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  GlaxoSmithKline plc. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Bharat Biotech o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Serum institute of India Pvt. Ltd o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Biological E. Limited. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Bio-Med o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Biological E Limited o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  CSL Limited o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Novartis AG o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Vaxcyte o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  GSBPL o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Taj Pharmaceuticals Limited. o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies  Bavarian Nordic o Company Highlights o Product Portfolio o Financial Performance o Recent Highlights o Market Strategies o Analyst Views 10. Section o References o Research Methodology o About Us

提及公司

Sanofi S.APfizer, Inc.Merck & Co., Inc.GlaxoSmithKline plc.Bharat BiotechSerum institute of India Pvt. Ltd.Biological E. LimitedBio-MedBavarian NordicCSL LimitedNovartis AGVaxcyteGSBPLTaj Pharmaceuticals LimitedBavarian Nordic

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們